NTRK1 and cancer: Inhibition of cholesterol hemostasis and lack of availability in cancer cells following leelamine treatment halts receptor tyrosine kinase signaling and prevents the activation of downstream PI3K/AKT, STAT3 and MAPK signaling cascades [12–14].